Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.15
$0.109.52%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -62.64% | -35.05% | -22.29% | -16.16% | -43.49% |
| Total Depreciation and Amortization | 16.97% | 8.86% | 18.13% | 46.23% | -74.71% |
| Total Amortization of Deferred Charges | 271.53% | 439.22% | 1,409.23% | 1,272.22% | 135.56% |
| Total Other Non-Cash Items | 2.44% | 24.13% | 15.35% | 8.44% | 13.25% |
| Change in Net Operating Assets | 374.83% | 333.90% | 96.35% | 103.93% | 89.14% |
| Cash from Operations | -47.51% | -26.10% | -13.79% | -2.11% | 8.45% |
| Capital Expenditure | -1,566.02% | -424.68% | -18.98% | -8.60% | 91.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.71% | -845.39% | -418.12% | -2,194.03% | -393.38% |
| Cash from Investing | 12.89% | -834.77% | -453.80% | -3,468.63% | -322.25% |
| Total Debt Issued | 213.53% | 209.26% | 2.37% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -101.03% |
| Issuance of Common Stock | 46.90% | 1,057.25% | 367.60% | 154.04% | -11.29% |
| Repurchase of Common Stock | -27.08% | -2.66% | 0.00% | 65.64% | 67.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.85% | 867.41% | 272.31% | 526.22% | 7.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.11% | 218.10% | 12.10% | 71.51% | -283.82% |